The authors wish to acknowledge the Observational Medical Outcomes Partnership (OMOP) investigators for their help in running the OMOP methods in the EU-ADR environment. The study was funded by The Foundation for the National Institutes of Health, grant STUR11OMOP. Dr. Schuemie received a fellowship from the Office of Medical Policy, Center for Drug Evaluation and Research, Food and Drug Administration, has become an employee of Janssen Research & Development since completing this research, and is an OMOP investigator. OMOP is funded by the Foundation for the National Institutes of Health through generous contributions from the following: Abbott, Amgen Inc., AstraZeneca, Bayer Healthcare Pharmaceuticals, Inc., Biogen Idec, Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, Janssen Research and Development, Lundbeck, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmaceutical Research Manufacturers of America (PhRMA), Roche, Sanofi-aventis, Schering-Plough Corporation, and Takeda. Mr. Straatman and Dr. Herings are employees of the PHARMO Institute for Drug Outcomes Research, which performs financially supported studies for several pharmaceutical companies. All other authors declare to have no conflicts of interests to declare. Dr. Sturkenboom is an employee of the Erasmus University Medical Center, and coordinates studies that are financially supported by several pharmaceutical companies (Novartis, Pfizer, EliLilly, Boehringer), none related to this study.
This article was published in a supplement sponsored by the Foundation for the National Institutes of Health (FNIH). The supplement was guest edited by Stephen J.W. Evans. It was peer reviewed by Olaf H. Klungel who received a small honorarium to cover out-of-pocket expenses. S.J.W.E has received travel funding from the FNIH to travel to the OMOP symposium and received a fee from FNIH for the review of a protocol for OMOP. O.H.K has received funding for the IMI-PROTECT project.from the Innovative Medicines Initiative Joint Undertaking (http://www.imi.europa.eu) under Grant Agreement no 115004, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.